CTOs on the Move

Nutritional Laboratories International

www.nutritionallabs.com

 
NLI offers: , Drug cGMP quality manufacturing processes , Superior laboratory support services following current Good Manufacturing Practices (cGMPs) , Disciplined and documented product design and engineering systems , Information-based customer
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Civica Rx

Civica Rx was created in late 2018 to secure the supply of important medicines hospitals use every day. As of Q2 2023, we have provided over 125 million units of essential medicines to hospitals, enough to help treat over 50 million patients. Recently, we announced we will manufacture and distribute affordable medications for consumers in an outpatient/retail setting, including affordable insulin. Insulin is an exciting project as we are partnering with nearly every corner of the diabetes ecosystem to bring low-cost insulin to people living with diabetes at no more than $30 a vial and no more than $55 for a pack of five pre-filled pens, regardless of insurance status.

Innovacon

Innovacon, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Headway Emotional Health Services

Our psychiatrists, case workers, and medical and administrative staff are dedicated to helping people in emotional distress transform their lives through treatment, intervention and education. Headways services include outpatient therapy, DBT, psychia...

Avitus Orthopaedics

Avitus Orthopaedics is a medical device company developing novel surgical instruments for minimally invasive tissue harvesting. Empower your fusions.

Adial Pharmaceuticals

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder (“AUD using our lead investigational new drug product, AD04. A Phase 2b University of Virginia investigator sponsored clinical trial of AD04 for the treatment of AUD showed promising results and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes.